| 1. |
- Albertsson-Lindblad, Alexandra, et al.
(författare)
-
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
- 2016
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 128:14, s. 1814-1820
-
Tidskriftsartikel (refereegranskat)abstract
- For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL. Patients >65 years with untreated MCL, stages II-IV were eligible for inclusion. Primary end points were maximally tolerable dose (MTD) of LEN and progression-free survival (PFS). Patients received 6 cycles every four weeks of L-B-R (L D1-14, B 90 mg/m(2) IV, days 1-2 and R 375 mg/m(2) IV, day 1) followed by single LEN (days 1-21, every four weeks, cycles 7-13). Fifty-one patients (median age 71 years) were enrolled from 2009 to 2013. In phase 1, the MTD of LEN was defined as 10 mg in cycles 2 through 6, and omitted in cycle 1. After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3-year overall survival was 73%. Infection was the most common nonhematologic grade 3 to 5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in 3 patients: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus retinitis. Second primary malignancies (SPM) were observed in 8 patients (16%). LEN could safely be combined with R-B when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs, which may limit its use. This trial is registered at www.Clinicaltrials.gov as #NCT00963534.
|
|
| 2. |
- Albertsson-Lindblad, Alexandra, et al.
(författare)
-
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
- 2016
-
Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 128:14, s. 1814-1820
-
Tidskriftsartikel (refereegranskat)abstract
- For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter open-label phase I/II trial we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment to elderly MCL patients. Patients >65 years with untreated MCL, stage II-IV were eligible for inclusion. Primary endpoints were maximally tolerable dose (MTD) of LEN, and progression-free survival (PFS). Patients received six cycles q4w of L-B-R (L D1-14, B 90 mg/m(2) iv D1-2 and R 375 mg/m(2) iv D1) followed by single LEN (D1-21, q4w, cycles 7-13). 51 patients (median age 71 years) were enrolled 2009-2013. In phase I, the MTD of LEN was defined as 10 mg in cycles 2-6, and omitted in cycle 1. After six cycles, the complete remission rate (CRR) was 64% and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3 year overall survival was 73%. Infection was the most common non-hematological grade 3-5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in three patients; 2 PCP and 1 CMV retinitis. Second primary malignancies (SPM) were observed in eight patients (16%). LEN could safely be combined with R-B, when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs which may limit its use. http://clinicaltrials.gov: NCT00963534.
|
|
| 3. |
- Andersson, Leif, et al.
(författare)
-
Den vita hästens gåta löst
- 2008
-
Ingår i: Forskning & Framsteg. ; :8, s. 40-43
-
Tidskriftsartikel (populärvet., debatt m.m.)
|
|
| 4. |
- Andersson, Leif, et al.
(författare)
-
ZBED6 : the birth of a new transcription factor in the common ancestor of placental mammals
- 2010
-
Ingår i: Transcription. - : Informa UK Limited. - 2154-1272 .- 2154-1264. ; 1:3, s. 144-148
-
Tidskriftsartikel (refereegranskat)abstract
- A DNA transposon integrated into -the genome of a primitive mammal some 200 million years ago and, millions of years later, it evolved an essential function in the common ancestor of all placental mammals. This protein, now named ZBED6, was recently discovered because a mutation disrupting one of its binding sites, in an intron of the IGF2 gene, makes pigs grow more muscle. These findings have revealed a new mechanism for regulating muscle growth as well as a novel transcription factor that appears to be of major importance for transcriptional regulation in placental mammals.
|
|
| 5. |
- Apel, Jan, 1965-, et al.
(författare)
-
Fågelbacken och trattbägarsamhället : samhällsorganisation och rituella samlingsplatser vid övergången till en bofats tillvaro i östra Mellansverige
- 1995
-
Ingår i: Tor. - Uppsala : Tor. - 0495-8772. ; 27, s. 47-132
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- A discussion of the TRB cultural landscape and form of society is attempted on the basis of the excavation of an Early Neolithic Funnel-beaker settlement site at Fågelbacken in eastern central Sweden. The site, situated on top of an esker, is characterized by finds of TRB pottery, quartz and flint debitage, pits with charred human bones, a cultbuilding and D-shaped huts. As a result of intra-site spatial analysis, ceramic analysis and a discussion of the site features, it is suggested that Fågelbacken should be interpreted not only as a coastal hunting site but also as a repeatedly visited, communal ritual site. A spatial analysis of thin-butted axes in the area surrounding the site, suggests that it is probably one of a whole series of similar, evenly spaced, ritual sites in the area. A sociocultural interpretation of Funnel-beaker huts and houses, together with an analysis of the distribution of stray finds of TRB type in the research area, further suggests that coastal sites like Fågelbacken are structurally related to groups of swidden-agriculture farmsteads and hunting stations in the interior.
|
|
| 6. |
|
|
| 7. |
- Baranowska Körberg, Izabella, et al.
(författare)
-
A Simple Repeat Polymorphism in the MITF-M Promoter Is a Key Regulator of White Spotting in Dogs
- 2014
-
Ingår i: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 9:8, s. e104363-
-
Tidskriftsartikel (refereegranskat)abstract
- The white spotting locus (S) in dogs is colocalized with the MITF (microphtalmia-associated transcription factor) gene. The phenotypic effects of the four S alleles range from solid colour (S) to extreme white spotting (s(w)). We have investigated four candidate mutations associated with the s(w) allele, a SINE insertion, a SNP at a conserved site and a simple repeat polymorphism all associated with the MITF-M promoter as well as a 12 base pair deletion in exon 1B. The variants associated with white spotting at all four loci were also found among wolves and we conclude that none of these could be a sole causal mutation, at least not for extreme white spotting. We propose that the three canine white spotting alleles are not caused by three independent mutations but represent haplotype effects due to different combinations of causal polymorphisms. The simple repeat polymorphism showed extensive diversity both in dogs and wolves, and allele-sharing was common between wolves and white spotted dogs but was non-existent between solid and spotted dogs as well as between wolves and solid dogs. This finding was unexpected as Solid is assumed to be the wild-type allele. The data indicate that the simple repeat polymorphism has been a target for selection during dog domestication and breed formation. We also evaluated the significance of the three MITF-M associated polymorphisms with a Luciferase assay, and found conclusive evidence that the simple repeat polymorphism affects promoter activity. Three alleles associated with white spotting gave consistently lower promoter activity compared with the allele associated with solid colour. We propose that the simple repeat polymorphism affects cooperativity between transcription factors binding on either flanking sides of the repeat. Thus, both genetic and functional evidence show that the simple repeat polymorphism is a key regulator of white spotting in dogs.
|
|
| 8. |
- Bentham, James, et al.
(författare)
-
A century of trends in adult human height
- 2016
-
Ingår i: eLIFE. - : eLife Sciences Publications Ltd. - 2050-084X. ; 5
-
Tidskriftsartikel (refereegranskat)abstract
- Being taller is associated with enhanced longevity, and higher education and earnings. We reanalysed 1472 population-based studies, with measurement of height on more than 18.6 million participants to estimate mean height for people born between 1896 and 1996 in 200 countries. The largest gain in adult height over the past century has occurred in South Korean women and Iranian men, who became 20.2 cm (95% credible interval 17.5–22.7) and 16.5 cm (13.3– 19.7) taller, respectively. In contrast, there was little change in adult height in some sub-Saharan African countries and in South Asia over the century of analysis. The tallest people over these 100 years are men born in the Netherlands in the last quarter of 20th century, whose average heights surpassed 182.5 cm, and the shortest were women born in Guatemala in 1896 (140.3 cm; 135.8– 144.8). The height differential between the tallest and shortest populations was 19-20 cm a century ago, and has remained the same for women and increased for men a century later despite substantial changes in the ranking of countries.
|
|
| 9. |
- Bergman, Åke, et al.
(författare)
-
Insamling och kemisk analys av miljöföroreningar i svensk modersmjölk - Resultat från 2008-2010 : Rapport till Naturvårdsverket – 2010-11-24
- 2010
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- Projekten, såsom det först formulerades, avsåg insamling av mjölkprover från mödrar boende i Stockholm, Göteborg, Lund respektive Umeå. Redan första året visade det sig svårt att få in prover från samtliga platser varför provinsamlingen 2008 -2010 koncentrerades till Göteborg och Stockholm. Prover från dessa städer har levererats till Naturhistoriska riksmuseet för dokumentering, preparering och lagring. Såväl individuella prover som poolade sådana har analyserats med avsikt att särskilt studera prover från Göteborg på individuell basis. Proverna för 2008 inkluderade 10 individuella prover och fyra homogenat och för prover från 2009/2010, 19 individuella prover samt två homogenat. De kemiska ämnen som analyserades tillhör följande klasser av miljöföroreningar: organiska klorpesticider, polyklorerade bifenyler (PCB) samt polybromerade difenyletrar (PBDE). Antalet enskilda analyter har i första hand avgjorts av ämnenas förekomst i proverna, men de som rapporteras är ett drygt 20-tal ämnen (se nedan).Den i särklass viktigaste miljöföroreningen bland de som här studeras är 4,4’-DDE. Den förekommer i halter mellan 20 och 130 ng/g fett, 2008-2010 i Göteborg medan halten i homogenat från 2007 låg på ca. 185 ng/g fett. I Stockholmsmödrarnas mjölk från 2008 låg halten på 70-80 ng/g fett men 2009/2010 var halten uppe i ca. 150 ng/g fett. De senare värdena ligger i paritet med observerade halter 2003, 2004 och 2007. Variationen är sådan att det inte ter sig finnas någon trend i haltutvecklingen mellan åren. Inte heller någon geografisk trend tycks förekomma, men fördjupade analyser av dessa data krävs för att säkerställa de statistiska observationerna. Övriga klororganiska bekämpningsmedel, inkl. hexaklorbensen (HCB) förekommer i halter som är <10% av 4,4’-DDE. De dominerande PCB-kongenerna är CB-138, -153 och -180 men dessa förekommer i halter som är lägre än 50% av det som 4,4’-DDE förekommer i. Flertalet PCB-kongener förekommer i sub-10 ng/g fett-halter i modersmjölken oavsett ursprungsstad (Göteborg eller Stockholm).ΣPCB-halten ligger i nivå med koncentrationen av 4,4’-DDE. Koncentrationerna av polybromerade difenyletrar (PBDE) är låga. De enskilda PBDE-kongenerna har mestadels halter på under 1 ng/g fett. BDE-209 förekommer mycket sällan i kvantifierbar halt i modersmjölken. Av lägre bromerade difenyletrar dominerar fortfarande BDE-47.Utanför kontraktet tillförs här också data för halter och trender av polyfluorerade kemikalier i modersmjölk från Stockholm 1972 till 2008. De ämnen som analyserats i modersmjölken är perfluorooktansulfonat (PFOS), perfluorohexansulfonat (PFHS) samt perfluorooktansyra (PFOA). Resultaten redovisar entydigt ämnenas uppåtgående trend fram till omkring 2000 varefter koncentrationerna faller.
|
|
| 10. |
|
|
